ABL1 and melanoma: When all melanoma cell lines (n = 28) were considered, the three subtypes showed a significantly different response (FDR < 0.05) to the MEK inhibitor AZD6244 (Figure 4A), to the SRC family kinase (SFK)/ABL dual-kinase inhibitor AZD0530 and to the ALK inhibitor TAE684 (Supplementary Table 5).